Figure 2.
Prognostic impact of SBS mutational signatures in LBCL treated with CAR-19. (A) Summary of all possible impacts of CD19 L174V mutation on tumor evolution after CAR-19. (B) Absence of prognostic impact of CD19 gene expression among 16 patients with available RNA-seq data. (C) The relative contribution of each mutational signature (color) per each sample (x-axis, 51 WGS samples). Asterisks indicate the presence of DBS5 (platinum chemotherapy treatment double-base substitution signature). (D) SBS mutational-signature contributions for each phylogenetic tree cluster (sample CAR_39). SBS mutational signature colors are the same as the legend to panel B. (E-F) The Kaplan-Meier plots of PFS comparing patients with (+) and without (−) APOBEC (E) and SBS18 (F) mutational signatures (n = 47).

Prognostic impact of SBS mutational signatures in LBCL treated with CAR-19. (A) Summary of all possible impacts of CD19 L174V mutation on tumor evolution after CAR-19. (B) Absence of prognostic impact of CD19 gene expression among 16 patients with available RNA-seq data. (C) The relative contribution of each mutational signature (color) per each sample (x-axis, 51 WGS samples). Asterisks indicate the presence of DBS5 (platinum chemotherapy treatment double-base substitution signature). (D) SBS mutational-signature contributions for each phylogenetic tree cluster (sample CAR_39). SBS mutational signature colors are the same as the legend to panel B. (E-F) The Kaplan-Meier plots of PFS comparing patients with (+) and without (−) APOBEC (E) and SBS18 (F) mutational signatures (n = 47).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal